Search

Displaying results 2201 - 2210 of 5506 in total
  1. Drug

    Goserelin

    go.drugbank.com/drugs/DB00014
    ApprovedInvestigational

    In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.

  2. Drug

    Bentiromide

    go.drugbank.com/drugs/DB00522
    ApprovedWithdrawn

    It is typically administered orally. Cases of headache and gastrointestinal disturbances have been reported with the use of bentiromide. Bentiromide is currently not available in the U.S. or Canada.

  3. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver

  4. Drug

    Betula papyrifera pollen

    go.drugbank.com/drugs/DB10831
    Approved

    Betula papyrifera pollen is the pollen of the Betula papyrifera plant. Betula papyrifera pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  5. Drug

    Ertapenem

    go.drugbank.com/drugs/DB00303
    ApprovedInvestigational

    [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002.

  6. Drug

    Polycarbophil

    go.drugbank.com/drugs/DB09311
    ApprovedWithdrawn

    It is insoluble in water, dilute acids, and dilute alkali.

  7. Drug

    Deferoxamine

    go.drugbank.com/drugs/DB00746
    ApprovedInvestigational

    It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.

  8. Drug

    Ferric pyrophosphate citrate

    go.drugbank.com/drugs/DB13995
    Approved

    [L1419] It is also FDA approved since 2015.[FDA label] … Free iron presents several side effects as it can catalyze free radical formation and lipid peroxidation as well as the presence of interactions of iron in plasma.

  9. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. … [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix].

  10. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes.